# Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC

> **NCT02501902** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 76 (actual)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Nab-Paclitaxel

## Key facts

- **NCT ID:** NCT02501902
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-23
- **Primary completion:** 2018-10-10
- **Final completion:** 2018-12-27
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2021-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02501902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02501902, "Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02501902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*